EQS-News: SYNLAB AG
/ Key word(s): Disposal
SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, today announced the sale of SYNLAB SUISSE SA to Sonic Healthcare (ASX:SHL; ADR:SKHHY), having received the required approvals of antitrust authorities.
“After a careful review of our activities in Switzerland and the developments in the diagnostics sector as a whole, SYNLAB Group decided to accept Sonic Healthcare’s offer for SYNLAB SUISSE SA and to sell all of our operations in Switzerland,” said Mathieu Floreani, CEO of the SYNLAB Group. “Efficient capital deployment is part of the SYNLAB strategy”, Mathieu continued. “Staying true to our strategy, we are applying an active portfolio management to optimise the SYNLAB network, aiming at a dense geographic footprint while benefitting from scale effects. This generates value for our stakeholders”, Mathieu added. Operations in Switzerland were expected to generate revenues of around €50 million in the second half year of 2023. The sale does not lead to a change in the Company’s FY 2023 revenue guidance of around €2.7 billion. This transaction also has a positive impact on the adjusted EBITDA margin of SYNLAB within the given FY 2023 guidance of 16-18% and will reduce the adjusted net debt of the Group by around CHF 150 million (around €154 million). With a national presence of laboratories in Switzerland, the combination of operations of SYNLAB SUISSE SA and Sonic Healthcare offers great potential to further improve the provision of diagnostic services to Swiss physicians in medical practice and hospitals. Mathieu Floreani: “Our highly skilled SYNLAB colleagues across our 26 locations are at the heart of the business we have built in Switzerland. We are thankful for their contributions and dedication and we are confident they will succeed in their new setup.” With the closing of the transaction expected for 3 July 2023, SYNLAB is in an even better position to provide leading diagnostic services to patients and healthcare professionals while at the same time ensuring continued profitable growth and scale. As diagnostics are highly important for healthcare systems around the world, SYNLAB will continue providing early detection, prevention, and personalised medicine for future-proof healthcare.
For more information:
About SYNLAB
Forward looking statements This document does not constitute or form a part of, and should not be construed as, an offer for sale or subscription of or solicitation of any offer to purchase or subscribe for any securities in any jurisdiction. Statements made in this document may include forward-looking statements. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words "believes", "expects”, “expected”, "may", "will", "would", "should", "seeks", "pro forma", "anticipates", "intends", "plans", "estimates", “estimated”, or the negative of any thereof or other variations thereof or comparable terminology, or by discussions of strategy or intentions. These statements are not guarantees of future actions or performance and involve risks, uncertainties and assumptions as to future events that may not prove to be accurate. Actual actions or results may differ materially from what is expressed or forecasted in these forward-looking statements. As a result, these statements speak only as of the date they were made and SYNLAB undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. It should be noted that past performance is not a guide to future performance. Interim results are not necessarily indicative of full-year results.
27.06.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
Language: | English |
Company: | SYNLAB AG |
Moosacher Straße 88 | |
80809 Munich | |
Germany | |
Phone: | +49 1701183753 |
E-mail: | ir@synlab.com |
Internet: | www.synlab.com/ |
ISIN: | DE000A2TSL71 |
WKN: | A2TSL7 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1666017 |
End of News | EQS News Service |
|
1666017 27.06.2023 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.